On July 9, 2002, the Women's Health Initiative released the results of its combined HRT trial — prematurely, to the press, before most physicians had been informed. The headline: HRT increases breast cancer risk and cardiovascular events. The result: millions of women stopped hormone therapy overnight, physicians stopped prescribing it, and a generation of women suffered through menopause without treatment that could have significantly improved their health and quality of life.
The story of the WHI is a story about how science can be catastrophically misapplied — and how that misapplication can harm millions of people for decades before the error is corrected.
What the WHI Actually Found
The WHI studied two populations: women who had hysterectomies and received estrogen alone, and women with intact uteruses who received conjugated equine estrogen plus medroxyprogesterone acetate (MPA), a synthetic progestin. The trial that was stopped early was the combination group.
The increased breast cancer risk was observed specifically in the combination group (estrogen + synthetic progestin) — not in the estrogen-alone group. In fact, the estrogen-alone arm showed a trend toward reduced breast cancer risk. The hormone being studied was conjugated equine estrogen — a mix of equine estrogens, not the human estradiol used in modern HRT. The progestin was MPA — one of the most problematic synthetic progestins, with androgenic properties and adverse metabolic effects that bioidentical progesterone does not share.
The average age of women in the WHI was 63. The average time since menopause was over 10 years. These were not recently menopausal women in the critical therapeutic window — they were elderly women, many with existing atherosclerosis, who were starting hormones for the first time decades after menopause. In this population, estrogen can destabilize arterial plaques that wouldn't be present in recently menopausal women.
The Timing Hypothesis
The most important development in HRT science since the WHI is the "timing hypothesis" — the recognition that the effects of estrogen therapy are profoundly different depending on when initiation occurs relative to menopause.
When estrogen is initiated within 10 years of menopause or before age 60 (the "critical window"), it is cardioprotective — reducing atherosclerosis, improving lipid profiles, reducing arterial stiffness, and decreasing inflammatory markers. When estrogen is initiated more than 10 years after menopause or after age 60, it is neutral to mildly adverse for cardiovascular outcomes — because atherosclerosis has already developed and estrogen can act on pre-existing plaques.
The WHI studied women who were, on average, far outside the critical window. The cardiovascular findings were real — for that population. Applying them to recently menopausal women in their 40s and early 50s was scientifically unwarranted.
What the Evidence Now Shows
The KEEPS trial (Kronos Early Estrogen Prevention Study) — specifically designed to address the WHI's limitations — studied recently menopausal women in their 40s and 50s using physiologic doses of transdermal estradiol or oral conjugated estrogens with micronized progesterone. Results showed no increase in cardiovascular risk, improvement in several cardiovascular markers, and improved quality of life and cognitive function.
The Danish Osteoporosis Prevention Study followed women for 10 years and found a significant reduction in cardiovascular events in women who started HRT within the critical window.
A 2022 meta-analysis in The Lancet Oncology reanalyzed breast cancer risk from HRT and found that the absolute risk increase for estrogen-alone therapy was extremely small and possibly absent. For combined therapy, the risk depended significantly on the type of progestogen used — bioidentical progesterone showing substantially lower risk than synthetic progestins.
Where We Are Now
Every major menopause society — The Menopause Society (formerly NAMS), the British Menopause Society, the European Menopause and Andropause Society — has revised its guidelines to reflect the post-WHI evidence. The consensus: HRT is safe and appropriate for most healthy women under 60 who are within 10 years of menopause and who have bothersome symptoms. The benefits generally outweigh the risks in this population. The fear generated by the 2002 WHI findings was disproportionate to the actual evidence and caused immeasurable harm by undertreating an entire generation of women.
If you stopped HRT because of the 2002 headlines, or if you were told HRT was dangerous, the science has changed. The conversation with your physician should be different today than it was then.